Observation of the Efficacy and Tolerance of Motens® (Lacidipine) in Patients With Essential Hypertension

Boehringer Ingelheim24,526 enrolled

Overview

Study of the efficacy and tolerance of Motens® (lacidipine) in patients with essential hypertension. To obtain information on the dosage used in practice and the tolerance at the start of treatment (12 weeks)

Study Type

OBSERVATIONAL

Enrollment

24,526

Conditions

Hypertension

Interventions

Motens® (lacidipine)DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Non-hospitalised patients of both sexes aged 18 years or more with essential hypertension requiring treatment according to the recommendations of the German League for Hypertension Exclusion Criteria: Patients who had the contraindications listed in the product information (the case report file contained a copy of the product information)

Outcomes

Primary Outcomes

Assessment of efficacy by the investigator on a 4-point verbal rating scale based on changes in blood pressure

Time frame: Up to 12 weeks after start of drug administration

Assessment of tolerability by investigator on a 4-point verbal rating scale

Time frame: Up to 12 weeks after start of drug administration

Number of patients with adverse events

Time frame: Up to 12 weeks after start of drug administration

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.